(Q33603404)

28 July 2017

1 reference

title

Advances in cancer vaccine development (English)

1 reference

28 July 2017

Herlyn D

1

1 reference

28 July 2017

Birebent B

series ordinal

2

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

31

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

66-78

1 reference

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Humoral immune response to p53 in malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Anti-idiotype immunization of cancer patients: modulation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Cancer. p53, guardian of the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Detection of high incidence of K-ras oncogenes during human colon tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

The current status of therapeutic HPV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Identification of colon-tumor-associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumor-cell/bacillus Calmette-Guérin vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

In vitro and clinical characterisation of a newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Tumor immunotherapy: the tumor cell as an antigen-presenting cell

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Specific immunotherapy of colorectal carcinoma with Newcastle-disease virus-modified autologous tumor cells prepared from resected liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Neonatal administration of idiotype or antiidiotype primes for protection against Escherichia coli K13 infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Is cancer dangerous to the immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Molecular cloning of murine monoclonal anti-idiotypic Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Regulation of Isotype Immunoglobulin Production by Adjuvants in Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

The role of interleukin-6 in mucosal IgA antibody responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Lymphokine control of in vivo immunoglobulin isotype selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

The CD40-CD154 system in anti-infective host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Antitumor responses induced by transgenic expression of CD40 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Structure, Chromosomal Location, and Expression Pattern of Three Mouse Genes Homologous to the Human MAGE Genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899909019264

10.3109/07853899909019264

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference